• Cat-intel
  • MedIntelliX
  • Resources
  • About Us
  • Request Free Sample ×

    Kindly complete the form below to receive a free sample of this Report

    Leading companies partner with us for data-driven Insights

    clients tt-cursor
    Hero Background

    Asia Pacific Gastrointestinal Drugs Market

    ID: MRFR/Pharma/0190-CR
    106 Pages
    Rahul Gotadki
    October 2017

    Asia-Pacific Gastrointestinal Drugs Market Research Report Information: By Drug Class (Acid Neutralizers, Laxatives & Antidiarrheal, Anti-Emetics, Antiulcer), Type Of Disease (Esophagus Diseases, Stomach Diseases, Intestinal Diseases, Rectum Diseases) Forecast till 2035

    Share:
    Download PDF ×

    We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

    Asia Pacific Gastrointestinal Drugs Market Infographic
    Purchase Options

    Asia Pacific Gastrointestinal Drugs Market Summary

    The Asia-Pacific Gastrointestinal Drugs market is projected to experience substantial growth from 9.69 USD Billion in 2024 to 22.5 USD Billion by 2035.

    Key Market Trends & Highlights

    Asia-Pacific Gastrointestinal Drugs Key Trends and Highlights

    • The market is expected to grow at a compound annual growth rate (CAGR) of 7.94% from 2025 to 2035.
    • By 2035, the market valuation is anticipated to reach 22.5 USD Billion, indicating robust demand for gastrointestinal therapies.
    • In 2024, the market is valued at 9.69 USD Billion, reflecting a solid foundation for future expansion.
    • Growing adoption of advanced therapeutic options due to increasing prevalence of gastrointestinal disorders is a major market driver.

    Market Size & Forecast

    2024 Market Size 9.69 (USD Million)
    2035 Market Size 22.5 (USD Million)
    CAGR (2025-2035) 7.94%

    Major Players

    Abbott, Allergan Plc, AstraZeneca, Eli Lilly Company, F. Hoffmann-La Roche Ltd, GlaxoSmithKline plc, Pfizer Inc, Valeant Pharmaceuticals

    Key Companies in the Asia Pacific Gastrointestinal Drugs Market market include

    Market Segmentation

    Key Players

    • Pharmaceutical Companies
    • Medical Devices Companies
    • Research and Development (R&D) Companies
    • Market Research and Consulting Service Providers
    • Potential Investors

    Intended Audience

    • Pharmaceutical Companies
    • Medical Devices Companies
    • Research and Development (R&D) Companies
    • Market Research and Consulting Service Providers
    • Potential Investors

    Regional Analysis

    • Pharmaceutical Companies
    • Medical Devices Companies
    • Research and Development (R&D) Companies
    • Market Research and Consulting Service Providers
    • Potential Investors

    Figure: Asia-Pacific Gastrointestinal Drugs Market, by Region, 2016 (%)

    • Pharmaceutical Companies
    • Medical Devices Companies
    • Research and Development (R&D) Companies
    • Market Research and Consulting Service Providers
    • Potential Investors

    Report Scope

    Attribute/Metric Details
      Market Size   USD 14,868 Million
      CAGR   8.60%
      Base Year   2021
      Forecast Period   2022-2030
      Historical Data   2020
      Forecast Units   Value (USD Million)
      Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
      Segments Covered   Drug Class and Type of Disease
      Geographies Covered   China, India, Republic of Korea, and Rest of Asia
      Key Vendors   Abbott, Allergan Plc, AstraZeneca, Eli lilly Company, F. Hoffmann-La Roche Ltd, GlaxoSmithKline plc, Pfizer Inc, Valeant Pharmaceuticals
      Key Market Opportunities   Initiatives in the research and development of innovative and advanced drugs
      Key Market Drivers   Increasing prevalence of GI diseases, rising geriatric population, and increasing investment in research & development

    Market Highlights

    Author
    Rahul Gotadki
    Assistant Manager

    He holds an experience of about 7+ years in Market Research and Business Consulting, working under the spectrum of Life Sciences and Healthcare domains. Rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. His expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. In addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives

    Leave a Comment
    Download Free Sample

    Kindly complete the form below to receive a free sample of this Report

    Case Study
    Chemicals and Materials